Arlene Morris

Insider · Director · COGT

Arlene Morris files insider transactions with the SEC as a director of Cogent Biosciences (COGT). We hold 1 disclosed purchase or sale filed since 16 May 2006, 1 of them in the last 90 days.

Files forCOGT
Disclosed buys and sells1 in all, 1 in the last 90 days
Last disclosure31 August 2026

Positions held

13 posts we hold — a term names its own dates; a run of filings only says when they filed

Filed 11 March 2021 — 27 August 2026Director · Cogent Biosciences (COGT)12 Form 4 lines · source: SEC Form 4
Filed 11 June 2015 — 3 August 2026Director · Palatin Technologies (PTN)34 Form 4 lines · source: SEC Form 4
Filed 4 February 2021 — 1 July 2026Director · Viridian Therapeutics, Inc.\DE (VRDN)7 Form 4 lines · source: SEC Form 4
Filed 6 May 2024 — 5 June 2026Director · Edgewise Therapeutics (EWTX)4 Form 4 lines · source: SEC Form 4
Filed 22 August 2016 — 3 January 2023Director · Viveve Medical (VIVE)14 Form 4 lines · source: SEC Form 4
Filed 26 July 2019 — 9 June 2020Director · Unum Therapeutics (UMRX)2 Form 4 lines · source: SEC Form 4
Filed 27 June 2018 — 21 May 2020Director · Miragen Therapeutics (MGEN)3 Form 4 lines · source: SEC Form 4
Filed 19 May 2016 — 7 November 2017Director · Dimension Therapeutics (DMTX)5 Form 4 lines · source: SEC Form 4
Filed 11 May 2016 — 11 May 2016Director · Viveve Medical (VIVMF)1 Form 4 line · source: SEC Form 4
Filed 15 May 2015 — 24 February 2016Director · Biodel (BIOD)2 Form 4 lines · source: SEC Form 4
Filed 2 April 2007 — 21 May 2013Director · Medicinova (MNOV)12 Form 4 lines · source: SEC Form 4
Filed 5 January 2007 — 22 September 2010CEO · Affymax (AFFY)204 Form 4 lines · source: SEC Form 4
Filed 11 May 2006 — 12 November 2006Director · Medicinova (4875 OSE)3 Form 4 lines · source: SEC Form 4

Everything they disclosed

120 entries, newest first — one per disclosure report, one per Form 4 line

exercised options over 41,927 shares of Cogent BiosciencesSEC Form 431 August 2026Common Stock · traded 27 August 2026 · filed 31 August 2026
exercised options over 3,583 shares of Cogent BiosciencesSEC Form 431 August 2026Common Stock · traded 27 August 2026 · filed 31 August 2026
▼ sold on the open market 42,349 shares of Cogent BiosciencesSEC Form 431 August 2026Common Stock · traded 27 August 2026 · filed 31 August 2026
▼ sold on the open market 3,161 shares of Cogent BiosciencesSEC Form 431 August 2026Common Stock · traded 27 August 2026 · filed 31 August 2026
exercised options over 41,927 shares of Cogent Biosciences (a derivative holding)SEC Form 431 August 2026Stock Option (Right to Buy) · traded 27 August 2026 · filed 31 August 2026
exercised options over 3,583 shares of Cogent Biosciences (a derivative holding)SEC Form 431 August 2026Stock Option (Right to Buy) · traded 27 August 2026 · filed 31 August 2026
filed a transaction coded Z in 2,400 shares of Palatin Technologies (a derivative holding)SEC Form 45 August 2026Stock Option (Right to Buy) · traded 3 August 2026 · filed 5 August 2026
was granted 32,341 shares of Viridian Therapeutics, Inc.\DE (a derivative holding)SEC Form 42 July 2026Stock Option (Right to Buy) · traded 1 July 2026 · filed 2 July 2026
was granted 16,377 shares of Edgewise Therapeutics (a derivative holding)SEC Form 417 June 2026Stock Option (Right to Buy) · traded 5 June 2026 · filed 17 June 2026
was granted 17,901 shares of Cogent Biosciences (a derivative holding)SEC Form 411 June 2026Stock Option (Right to Buy) · traded 9 June 2026 · filed 11 June 2026
was granted 2,400 shares of Palatin Technologies (a derivative holding)SEC Form 411 December 2025Stock Option (Right to Buy) · traded 9 December 2025 · filed 11 December 2025
was granted 2,400 shares of Palatin Technologies (a derivative holding)SEC Form 411 December 2025Stock Option (Right to Buy) · traded 9 December 2025 · filed 11 December 2025
was granted 21,000 shares of Viridian Therapeutics, Inc.\DE (a derivative holding)SEC Form 42 July 2025Stock Option (Right to Buy) · traded 1 July 2025 · filed 2 July 2025
was granted 30,000 shares of Edgewise Therapeutics (a derivative holding)SEC Form 418 June 2025Stock Option (Right to Buy) · traded 16 June 2025 · filed 18 June 2025
was granted 44,700 shares of Cogent Biosciences (a derivative holding)SEC Form 45 June 2025Stock Option (Right to Buy) · traded 4 June 2025 · filed 5 June 2025
was granted 17,000 shares of Palatin Technologies (a derivative holding)SEC Form 416 July 2024Stock Option (Right to Buy) · traded 15 July 2023 · filed 16 July 2024
was granted 12,000 shares of Palatin TechnologiesSEC Form 416 July 2024Common Stock · traded 15 July 2024 · filed 16 July 2024
was granted 21,000 shares of Viridian Therapeutics, Inc.\DE (a derivative holding)SEC Form 428 June 2024Stock Option (Right to Buy) · traded 26 June 2024 · filed 28 June 2024
was granted 44,700 shares of Cogent Biosciences (a derivative holding)SEC Form 413 June 2024Stock Option (Right to Buy) · traded 5 June 2024 · filed 13 June 2024
was granted 20,594 shares of Edgewise Therapeutics (a derivative holding)SEC Form 412 June 2024Stock Option (Right to Buy) · traded 10 June 2024 · filed 12 June 2024
was granted 34,311 shares of Edgewise Therapeutics (a derivative holding)SEC Form 47 May 2024Stock Options (Right to buy) · traded 6 May 2024 · filed 7 May 2024
was granted 16,000 shares of Palatin Technologies (a derivative holding)SEC Form 422 June 2023Stock Option (Right to Buy) · traded 20 June 2023 · filed 22 June 2023
was granted 10,000 shares of Palatin TechnologiesSEC Form 422 June 2023Common Stock · traded 20 June 2023 · filed 22 June 2023
was granted 20,000 shares of Viridian Therapeutics, Inc.\DE (a derivative holding)SEC Form 416 June 2023Stock Option (Right to Buy) · traded 14 June 2023 · filed 16 June 2023
was granted 36,700 shares of Cogent Biosciences (a derivative holding)SEC Form 48 June 2023Stock Option (Right to Buy) · traded 7 June 2023 · filed 8 June 2023
was granted 36,000 shares of Viveve Medical (a derivative holding)SEC Form 45 January 2023Restricted Stock Unit · traded 3 January 2023 · filed 5 January 2023
was granted 128,000 shares of Palatin Technologies (a derivative holding)SEC Form 424 June 2022Stock Option (Right to Buy) · traded 22 June 2022 · filed 24 June 2022
was granted 73,000 shares of Palatin TechnologiesSEC Form 424 June 2022Common Stock · traded 22 June 2022 · filed 24 June 2022
was granted 12,500 shares of Viridian Therapeutics, Inc.\DE (a derivative holding)SEC Form 410 June 2022Stock Option (Right to Buy) · traded 8 June 2022 · filed 10 June 2022
was granted 30,700 shares of Cogent Biosciences (a derivative holding)SEC Form 49 June 2022Stock Option (Right to Buy) · traded 7 June 2022 · filed 9 June 2022
was granted 22,000 shares of Viveve Medical (a derivative holding)SEC Form 46 January 2022Non-Qualified Stock Option (Right to Purchase) · traded 4 January 2022 · filed 6 January 2022
▲ bought on the open market 33,000 shares of Palatin TechnologiesSEC Form 42 July 2021Common stock · traded 1 July 2021 · filed 2 July 2021
was granted 33,000 shares of Palatin TechnologiesSEC Form 41 July 2021Common stock · traded 1 July 2021 · filed 1 July 2021
was granted 51,700 shares of Viveve Medical (a derivative holding)SEC Form 425 June 2021Non-Qualified Stock Option (Right to Purchase) · traded 23 June 2021 · filed 25 June 2021
was granted 77,000 shares of Palatin TechnologiesSEC Form 424 June 2021Common stock · traded 22 June 2021 · filed 24 June 2021
was granted 128,000 shares of Palatin Technologies (a derivative holding)SEC Form 424 June 2021Stock option (right to buy) · traded 22 June 2021 · filed 24 June 2021
was granted 12,500 shares of Viridian Therapeutics, Inc.\DE (a derivative holding)SEC Form 416 June 2021Stock Option (Right to Buy) · traded 3 June 2021 · filed 16 June 2021
was granted 60,000 shares of Cogent Biosciences (a derivative holding)SEC Form 415 March 2021Stock Option (Right to Buy) · traded 11 March 2021 · filed 15 March 2021
was granted 25,000 shares of Viridian Therapeutics, Inc.\DE (a derivative holding)SEC Form 48 February 2021Director Stock Option (Right to Buy) · traded 4 February 2021 · filed 8 February 2021
was granted 25,000 shares of Viveve Medical (a derivative holding)SEC Form 422 January 2021Restricted Stock Unit · traded 20 January 2021 · filed 22 January 2021
was granted 165,000 shares of Viveve Medical (a derivative holding)SEC Form 422 September 2020Non-Qualified Stock Option (Right to Purchase) · traded 21 September 2020 · filed 22 September 2020
was granted 127,000 shares of Palatin Technologies (a derivative holding)SEC Form 418 June 2020Stock Option (Right to Buy) · traded 16 June 2020 · filed 18 June 2020
was granted 73,000 shares of Palatin TechnologiesSEC Form 418 June 2020Common Stock · traded 16 June 2020 · filed 18 June 2020
was granted 14,331 shares of Unum Therapeutics (a derivative holding)SEC Form 411 June 2020Stock Option (Right to Buy) · traded 9 June 2020 · filed 11 June 2020
was granted 24,000 shares of Miragen Therapeutics (a derivative holding)SEC Form 422 May 2020Stock Option (right to buy) · traded 21 May 2020 · filed 22 May 2020
was granted 330,000 shares of Viveve Medical (a derivative holding)SEC Form 427 November 2019Non-Qualified Stock Option (Right to Buy) · traded 26 November 2019 · filed 27 November 2019
was granted 28,661 shares of Unum Therapeutics (a derivative holding)SEC Form 429 July 2019Stock Option (Right to Buy) · traded 26 July 2019 · filed 29 July 2019
was granted 52,000 shares of Palatin Technologies (a derivative holding)SEC Form 426 June 2019Stock Option (right to buy) · traded 24 June 2019 · filed 26 June 2019
was granted 32,000 shares of Palatin TechnologiesSEC Form 426 June 2019Common Stock · traded 24 June 2019 · filed 26 June 2019
was granted 12,000 shares of Miragen Therapeutics (a derivative holding)SEC Form 421 June 2019Stock Option (right to buy) · traded 19 June 2019 · filed 21 June 2019
was granted 35,000 shares of Viveve Medical (a derivative holding)SEC Form 431 May 2019Non-Qualified Stock Option (Right to Purchase) · traded 29 May 2019 · filed 31 May 2019
▲ bought on the open market 9,600 shares of Palatin TechnologiesSEC Form 421 November 2018Common Stock · traded 20 November 2018 · filed 21 November 2018
▲ bought on the open market 100 shares of Palatin TechnologiesSEC Form 421 November 2018Common Stock · traded 20 November 2018 · filed 21 November 2018
▲ bought on the open market 100 shares of Palatin TechnologiesSEC Form 421 November 2018Common Stock · traded 20 November 2018 · filed 21 November 2018
▲ bought on the open market 2,100 shares of Palatin TechnologiesSEC Form 421 November 2018Common Stock · traded 20 November 2018 · filed 21 November 2018
▲ bought on the open market 100 shares of Palatin TechnologiesSEC Form 421 November 2018Common Stock · traded 20 November 2018 · filed 21 November 2018
was granted 17,500 shares of Viveve Medical (a derivative holding)SEC Form 425 October 2018Non-qualified Stock Option (Right to Purchase) · traded 23 October 2018 · filed 25 October 2018
was granted 12,000 shares of Miragen Therapeutics (a derivative holding)SEC Form 428 June 2018Stock Option (right to buy) · traded 27 June 2018 · filed 28 June 2018
was granted 28,000 shares of Palatin Technologies (a derivative holding)SEC Form 428 June 2018Stock Option (right to buy) · traded 26 June 2018 · filed 28 June 2018
was granted 28,000 shares of Palatin TechnologiesSEC Form 428 June 2018Common Stock · traded 26 June 2018 · filed 28 June 2018
was granted 17,500 shares of Viveve Medical (a derivative holding)SEC Form 423 May 2018Non-qualified Stock Option (Right to Purchase) · traded 22 May 2018 · filed 23 May 2018
was granted 30,000 shares of Palatin TechnologiesSEC Form 413 December 2017Common Stock · traded 12 December 2017 · filed 13 December 2017
was granted 30,000 shares of Palatin Technologies (a derivative holding)SEC Form 413 December 2017Stock Option (right to buy) · traded 12 December 2017 · filed 13 December 2017
returned to the issuer 44,474 shares of Dimension Therapeutics (a derivative holding)SEC Form 47 November 2017Stock Option (Right to Buy) · traded 7 November 2017 · filed 7 November 2017
returned to the issuer 32,069 shares of Dimension Therapeutics (a derivative holding)SEC Form 47 November 2017Stock Option (Right to Buy) · traded 7 November 2017 · filed 7 November 2017
returned to the issuer 17,000 shares of Dimension Therapeutics (a derivative holding)SEC Form 47 November 2017Stock Option (Right to Buy) · traded 7 November 2017 · filed 7 November 2017
was granted 17,500 shares of Viveve Medical (a derivative holding)SEC Form 48 September 2017Non-qualified Stock Option (Right to Purchase) · traded 6 September 2017 · filed 8 September 2017
was granted 54,000 shares of Palatin TechnologiesSEC Form 422 June 2017Common Stock · traded 20 June 2017 · filed 22 June 2017
was granted 54,000 shares of Palatin Technologies (a derivative holding)SEC Form 422 June 2017Stock Option (right to buy) · traded 20 June 2017 · filed 22 June 2017
was granted 17,000 shares of Dimension Therapeutics (a derivative holding)SEC Form 426 May 2017Stock Option (Right to Buy) · traded 25 May 2017 · filed 26 May 2017
was granted 25,160 shares of Viveve Medical (a derivative holding)SEC Form 428 December 2016Non-qualified Stock Option (Right to Purchase) · traded 23 December 2016 · filed 28 December 2016
was granted 1,442 shares of Viveve MedicalSEC Form 414 November 2016Common Stock · traded 9 November 2016 · filed 14 November 2016
was granted 1,040 shares of Viveve MedicalSEC Form 424 August 2016Common Stock · traded 22 August 2016 · filed 24 August 2016
was granted 4,590 shares of Viveve Medical (a derivative holding)SEC Form 424 August 2016Non-Qualified Stock Option (Right to Purchase) · traded 22 August 2016 · filed 24 August 2016
was granted 37,500 shares of Palatin TechnologiesSEC Form 413 June 2016Common Stock · traded 9 June 2016 · filed 13 June 2016
exercised options over 20,000 shares of Palatin TechnologiesSEC Form 413 June 2016Common Stock · traded 13 June 2016 · filed 13 June 2016
was granted 37,500 shares of Palatin Technologies (a derivative holding)SEC Form 413 June 2016Stock Option (right to buy) · traded 9 June 2016 · filed 13 June 2016
was granted 32,069 shares of Dimension Therapeutics (a derivative holding)SEC Form 423 May 2016Stock Option (Right to Buy) · traded 19 May 2016 · filed 23 May 2016
was granted 5,250 shares of Viveve Medical (a derivative holding)SEC Form 420 May 2016Non-Qualified Stock Option (Right to Purchase) · traded 11 May 2016 · filed 20 May 2016
was granted 100,000 shares of Biodel (a derivative holding)SEC Form 48 March 2016Stock Option (right to buy) · traded 24 February 2016 · filed 8 March 2016
was granted 20,000 shares of Palatin TechnologiesSEC Form 410 December 2015Common Stock · traded 8 December 2015 · filed 10 December 2015
was granted 20,000 shares of Palatin Technologies (a derivative holding)SEC Form 412 June 2015stock option (right to buy) · traded 11 June 2015 · filed 12 June 2015
was granted 20,000 shares of Palatin Technologies (a derivative holding)SEC Form 412 June 2015restricted share units · traded 11 June 2015 · filed 12 June 2015
was granted 10,000 shares of Biodel (a derivative holding)SEC Form 419 May 2015Stock Option (right to buy) · traded 15 May 2015 · filed 19 May 2015
exercised options over 1,000 shares of Medicinova (a derivative holding)SEC Form 423 May 2013Stock Option (Right to Buy) · traded 21 May 2013 · filed 23 May 2013
exercised options over 7,800 shares of Medicinova (a derivative holding)SEC Form 423 May 2013Stock Option (Right to Buy) · traded 21 May 2013 · filed 23 May 2013
exercised options over 1,000 shares of MedicinovaSEC Form 423 May 2013Common Stock · traded 21 May 2013 · filed 23 May 2013
exercised options over 7,800 shares of MedicinovaSEC Form 423 May 2013Common Stock · traded 21 May 2013 · filed 23 May 2013
▼ sold on the open market 8,800 shares of MedicinovaSEC Form 423 May 2013Common Stock · traded 21 May 2013 · filed 23 May 2013
was granted 14,000 shares of Medicinova (a derivative holding)SEC Form 420 July 2011Stock Option (Right to Buy) · traded 18 July 2011 · filed 20 July 2011
was granted 30,000 shares of Medicinova (a derivative holding)SEC Form 420 July 2011Stock Option (Right to Buy) · traded 18 July 2011 · filed 20 July 2011
was granted 1,000 shares of Medicinova (a derivative holding)SEC Form 428 June 2011Stock Option (Right to Buy) · traded 14 June 2011 · filed 28 June 2011
was granted 100,000 shares of Affymax (a derivative holding)SEC Form 424 September 2010Stock Option (Right to Buy) · traded 22 September 2010 · filed 24 September 2010
was granted 75,000 shares of AffymaxSEC Form 424 September 2010Common Stock · traded 22 September 2010 · filed 24 September 2010
was granted 1,000 shares of Medicinova (a derivative holding)SEC Form 415 June 2010Stock Option (right to buy) · traded 11 June 2010 · filed 15 June 2010
exercised options over 1,066 shares of Affymax (a derivative holding)SEC Form 419 May 2010Stock Option (Right to Buy) · traded 17 May 2010 · filed 19 May 2010
exercised options over 2,229 shares of Affymax (a derivative holding)SEC Form 419 May 2010Stock Option (Right to Buy) · traded 18 May 2010 · filed 19 May 2010
exercised options over 26,666 shares of Affymax (a derivative holding)SEC Form 419 May 2010Stock Option (Right to Buy) · traded 18 May 2010 · filed 19 May 2010
exercised options over 22,935 shares of Affymax (a derivative holding)SEC Form 419 May 2010Stock Option (Right to Buy) · traded 18 May 2010 · filed 19 May 2010
exercised options over 1,066 shares of AffymaxSEC Form 419 May 2010Common Stock · traded 17 May 2010 · filed 19 May 2010
▼ sold on the open market 966 shares of AffymaxSEC Form 419 May 2010Common Stock · traded 17 May 2010 · filed 19 May 2010
▼ sold on the open market 100 shares of AffymaxSEC Form 419 May 2010Common Stock · traded 17 May 2010 · filed 19 May 2010
exercised options over 2,229 shares of AffymaxSEC Form 419 May 2010Common Stock · traded 18 May 2010 · filed 19 May 2010
exercised options over 26,666 shares of AffymaxSEC Form 419 May 2010Common Stock · traded 18 May 2010 · filed 19 May 2010
exercised options over 22,935 shares of AffymaxSEC Form 419 May 2010Common Stock · traded 18 May 2010 · filed 19 May 2010
▼ sold on the open market 51,830 shares of AffymaxSEC Form 419 May 2010Common Stock · traded 18 May 2010 · filed 19 May 2010
exercised options over 30,081 shares of Affymax (a derivative holding)SEC Form 413 May 2010Stock Option (Right to Buy) · traded 11 May 2010 · filed 13 May 2010
exercised options over 6,060 shares of Affymax (a derivative holding)SEC Form 413 May 2010Stock Option (Right to Buy) · traded 12 May 2010 · filed 13 May 2010
exercised options over 103,248 shares of Affymax (a derivative holding)SEC Form 413 May 2010Stock Option (Right to Buy) · traded 12 May 2010 · filed 13 May 2010
exercised options over 41,021 shares of Affymax (a derivative holding)SEC Form 413 May 2010Stock Option (Right to Buy) · traded 13 May 2010 · filed 13 May 2010
exercised options over 30,081 shares of AffymaxSEC Form 413 May 2010Common Stock · traded 11 May 2010 · filed 13 May 2010
▼ sold on the open market 29,581 shares of AffymaxSEC Form 413 May 2010Common Stock · traded 11 May 2010 · filed 13 May 2010
▼ sold on the open market 400 shares of AffymaxSEC Form 413 May 2010Common Stock · traded 11 May 2010 · filed 13 May 2010
▼ sold on the open market 100 shares of AffymaxSEC Form 413 May 2010Common Stock · traded 11 May 2010 · filed 13 May 2010
exercised options over 6,060 shares of AffymaxSEC Form 413 May 2010Common Stock · traded 12 May 2010 · filed 13 May 2010
exercised options over 103,248 shares of AffymaxSEC Form 413 May 2010Common Stock · traded 12 May 2010 · filed 13 May 2010
▼ sold on the open market 28,400 shares of AffymaxSEC Form 413 May 2010Common Stock · traded 12 May 2010 · filed 13 May 2010
▼ sold on the open market 80,908 shares of AffymaxSEC Form 413 May 2010Common Stock · traded 12 May 2010 · filed 13 May 2010
exercised options over 41,021 shares of AffymaxSEC Form 413 May 2010Common Stock · traded 13 May 2010 · filed 13 May 2010
▼ sold on the open market 41,021 shares of AffymaxSEC Form 413 May 2010Common Stock · traded 13 May 2010 · filed 13 May 2010

Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.